References
- Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352, 987–996 (2005).
- Gallia GL, Brem S, Brem H. Local treatment of malignant brain tumors using implantable chemotherapeutic polymers. J. Natl Compr. Canc. Netw.3, 721–728 (2005).
- Debinski W. Local treatment of brain tumors with targeted chimera cytotoxic proteins. Cancer Invest.20, 801–809 (2002).
- Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK. Human glioma cells over-express receptor for IL13 and are extremely sensitive to a novel chimeric protein composed of IL13 and Pseudomonas exotoxin. Clin. Cancer Res.1, 1253–1258 (1995).
- Kunwar S, Prados MD, Chang SM et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J. Clin. Oncol.25, 837–844 (2007).
- Kunwar S, Westphal M, Medhorn M et al. Results from PRECISE: a randomized Phase 3 study in patients with first recurrent GBM comparing Cintredekin Besudotox administered via convection-enhanced delivery with Gliadel wafers. Neuro-oncology9, 531 (2007).
- Saikali S, Avril T, Collet B et al. Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Rα2, gp100 and TRP-2 for immunotherapy. J. Neurooncol.81, 139–148 (2007).
- Zhang JG, Eguchi J, Kruse C et al. Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin. Cancer Res.13, 566–575 (2007).
- Liu TF, Tatter SB, Willingham MC, Yang MY, Hu J, Frankel A. Growth factor expression varies among high grade gliomas and normal brain: epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy. Mol. Cancer Ther.2(8), 783–787 (2003).
- Wykosky J, Gibo DM, Stanton C, Debinski W. IL-13 Receptor α-2, EphA2, and Fra-1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin. Cancer Res.14, 199–208 (2008).
- Nutt CL, Mani DR, Betensky RA et al. Gene expression-based classification of malignant gliomas correlated better with survival than histological classification. Cancer Res.63, 1602–1607 (2003).
- Wykosky J, Gibo DM, Stanton C, Debinski W. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol. Cancer Res.3, 541–551 (2005).
- Liu F, Park PJ, Lai W et al. A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma. Cancer Res.66, 10815–10823 (2006).
- Wykosky J, Gibo DM, Debinski W. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor-expressing tumor cells. Mol. Cancer Ther.6, 3208–3218 (2007 )
- Liu TF, Willingham MC, Tatter SB et al. Combination fusion protein therapy of refractory brain tumors: demonstration of efficacy in cell culture. J. Neurooncol.65(1), 77–85 (2003).
- Stish BJ, Chen H, Shu Y, Panoskaltsis-Mortari A, Vallera DA. Anti-glioblastoma effect of a recombinant bi-specific cytotoxin co-targeting human IL-13 and EGF receptors in a mouse xenograft model. J. Neurooncol.87(1), 51–61 (2008).
- Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell11(1), 83–95 (2007).
- Debinski W, Slagle-Webb B, Achen MG et al. VEGF-D is an X-linked/AP-1 regulated putative onco-angiogen in human glioblastoma multiforme. Mol. Med.7, 598–608 (2001).
- Mischel PS, Cloughesy T. Using molecular information to guide brain tumor therapy. Nat. Clin. Pract. Neurol.2(5), 232–233 (2006).
- Debinski W. Personalized, multivalent, and more affordable: the globalization of vaccines. Clin. Cancer Res.11, 5663–5664 (2005).